Could probiotics tame Chemo's worst symptoms?
NCT ID NCT06772090
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether taking probiotic supplements can help reduce common chemotherapy side effects like nausea, diarrhea, and loss of appetite in people with stage III colon cancer. Forty adults will be randomly assigned to receive either probiotics or a placebo during their chemo treatment. The main goal is to see if a larger, more definitive trial is even possible, so results will focus on how many people complete the study and how many side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Probiotic supplement (Lactobacillus and Bifidobacterium)
- What this could lead to
- If it works, this could point toward a simple way to reduce common chemo side effects like nausea and diarrhea for people with colon cancer.
- What could go wrong
- This is a very small, early feasibility trial with only 40 people. It is designed to test whether a larger study is possible, not to prove the probiotics work. Results may not apply to other cancers or treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOTOXICITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Zinc-Based compound fight cancer?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?
- New imaging agent aims to light up hidden tumors
- Could a new mouthwash formula be kinder to your gums?
- Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial